Glaxosmithkline Pharmaceuticals Share Price Target 2026, 2027, 2030, 2040, 2050
GlaxoSmithKline Pharmaceuticals makes and sells medicines and vaccines, and is one of the top medicine companies in India. It works on diseases like infections, HIV, cancer, and immune system problems. It provides general medicines like painkillers, anti-infectives, skin medicines, and vitamins; vaccines for babies, teens, and adults for diseases like hepatitis, flu, chickenpox, and tetanus; and special medicines for breathing problems and HIV. The company has a factory in Nashik, works with other makers, and has a big network to deliver medicines all over India. Its goal is to help people stay healthy, feel better, and live longer.
What is Glaxosmi Pharma Ltd NSE: GLAXO?
GlaxoSmithKline Pharmaceuticals was established in 1924 in Mumbai, Maharashtra and is owned by the global GSK group. It is a big Indian medicine company that makes and sells many types of medicines and vaccines. These include common medicines, special medicines for breathing problems, HIV, and cancer, and vaccines for diseases like hepatitis, flu, chickenpox, and cervical cancer. Over time, the company has grown, added vaccines and cancer treatments, and is now one of India’s leading companies in making medicines and keeping people healthy.
It works as a biopharma company under the bigger global GSK group. After separating its consumer healthcare business, it now focuses fully on prescription medicines, vaccines, and special treatments. The company combines research, making products, and distribution in one system, which helps it deliver medicines efficiently. This setup allows faster decisions, quicker innovation, and better response to India’s healthcare needs while following global standards and best practices. In 2026, its share price target would be ₹3517, as per stock market analysts.
According to stock market analysts, its share price would be between ₹1928 to ₹3517 in 2026.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 1928 | 3517 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 2165 | 2465 |
| February | 2284 | 2652 |
| March | 2162 | 2517 |
| April | 2205 | 2467 |
| May | 2194 | 2457 |
| June | 2088 | 2409 |
| July | 2243 | 2737 |
| August | 2080 | 2964 |
| September | 1928 | 3145 |
| October | 2293 | 3257 |
| November | 2667 | 3441 |
| December | 2935 | 3517 |
The company focuses on four main health areas: infectious diseases, HIV, cancer, and immune system problems. It also works on breathing problems and inflammation-related conditions. The company develop medicines and vaccines for both common sicknesses and serious diseases. It provides high-quality treatments and preventive care, making it a leader in regular medicines as well as advanced speciality treatments in India. In 2027, its share price target would be ₹6435, as per stock market analysts.
Its share price would be between ₹4889 to ₹6435 in 2027, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 4889 | 6435 |
It provides many general medicines for people of all ages. Its products include anti-infectives to fight infections, painkillers, skin medicines, and vitamins for overall health. These medicines help treat everyday sicknesses, keep people healthy, and boost immunity. Its medicines are of high quality and available widely. It helps millions of people get important treatments, supports hospitals and clinics, and improves public health across India. In 2028, its share price target would be ₹7733, as per stock market analysts.
Its share price would be between ₹6258 to ₹7733 in 2028, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 6258 | 7733 |
Vaccines are a very important part of the company. It provides vaccines for babies, children, teenagers, and adults to protect them from diseases like hepatitis, flu, chickenpox, and tetanus. Vaccines prevent serious illnesses and stop the spread of infections. It invests in research to make safe and effective vaccines for people in India. Through vaccines, the company supports health programs and makes preventive care available to communities all over the country. In 2029, its share price target would be ₹9007, as per stock market analysts.
Its share price would be between ₹7600 to ₹9007 in 2029, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 7600 | 9007 |
The company invests in science, including research on the immune system, genetics, and new technologies. Its R&D focuses on infectious diseases, cancer, breathing problems, HIV, and immune system disorders. This helps the company create new medicines and vaccines that meet India’s health needs today and in the future. It stays at the front of medical innovation and gives patients access to advanced treatments. In 2030, its share price target would be ₹10560, as per stock market analysts.
Its share price would be between ₹8852 to ₹10560 in 2030, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 8852 | 10560 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 8852 | 9225 |
| February | 8910 | 9384 |
| March | 9000 | 9487 |
| April | 9087 | 9620 |
| May | 9325 | 9732 |
| June | 9515 | 9952 |
| July | 9741 | 10084 |
| August | 9790 | 10174 |
| September | 9857 | 10220 |
| October | 9980 | 10342 |
| November | 10020 | 10389 |
| December | 10151 | 10560 |
It has a strong distribution system that reaches all parts of India. It includes regional warehouses, local distributors, and sales centres to deliver medicines and vaccines quickly and reliably. This system helps doctors and hospitals in both cities and rural areas, so patients get the treatments they need. The company ensures its products are available widely, improving health and supporting India’s healthcare system. In 2040, its share price target would be ₹17524, as per stock market analysts.
Its share price would be between ₹15782 to ₹17524 in 2040, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 15782 | 17524 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 15782 | 16085 |
| February | 15890 | 16175 |
| March | 15921 | 16258 |
| April | 15978 | 16284 |
| May | 16020 | 16354 |
| June | 16121 | 16400 |
| July | 16221 | 16575 |
| August | 16284 | 16721 |
| September | 16358 | 16889 |
| October | 16412 | 16947 |
| November | 16584 | 17254 |
| December | 16847 | 17524 |
The company wants to expand its vaccines and special medicines to meet India’s changing health needs. It works to prevent diseases, improve patient care, and provide advanced treatments for serious and long-term conditions. Its goal is to make healthcare more effective and accessible, helping people stay healthier, feel better, and live longer while remaining a trusted partner in India’s healthcare system. In 2050, its share price target would be ₹23573, as per stock market analysts.
Its share price would be between ₹22105 to ₹23573 in 2050, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 22105 | 23573 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 22105 | 22400 |
| February | 22187 | 22489 |
| March | 22220 | 22557 |
| April | 22284 | 22635 |
| May | 22354 | 22684 |
| June | 22412 | 22785 |
| July | 22510 | 22890 |
| August | 22574 | 23000 |
| September | 22625 | 23110 |
| October | 22841 | 23178 |
| November | 22910 | 23288 |
| December | 23080 | 23573 |
Should I buy Glaxosmi Pharma stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 1928 | 3517 |
| 2027 | 4889 | 6435 |
| 2028 | 6258 | 7733 |
| 2029 | 7600 | 9007 |
| 2030 | 8852 | 10560 |
| 2040 | 15782 | 17524 |
| 2050 | 22105 | 23573 |
It could be a safe choice if you want to invest for a few years. The company makes regular medicines, vaccines, and special treatments, and it has grown well recently. People always need its products, so the business is steady. Its strong points are a trusted name, regular sales, and chances to grow in new treatments. But there are some risks, like high stock prices, government rules, competition, and market ups and downs. It may not give quick profits, but it is good for steady long-term growth in healthcare.
Glaxosmi Pharma earnings results
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
| Sales + | 3,224 | 2,926 | 3,278 | 3,252 | 3,454 | 3,749 | 3,709 |
| Expenses + | 2,567 | 2,327 | 2,516 | 2,447 | 2,545 | 2,570 | 2,497 |
| Operating Profit | 657 | 598 | 762 | 804 | 909 | 1,179 | 1,212 |
| OPM % | 20% | 20% | 23% | 25% | 26% | 31% | 33% |
| Other Income + | -262 | 9 | 1,401 | 103 | -21 | 149 | 156 |
| Interest | 6 | 4 | 2 | 2 | 2 | 1 | 2 |
| Depreciation | 83 | 79 | 68 | 66 | 70 | 67 | 66 |
| Profit before tax | 306 | 525 | 2,093 | 839 | 816 | 1,260 | 1,300 |
| Tax % | 70% | 32% | 19% | 27% | 28% | 26% | |
| Net Profit + | 93 | 358 | 1,695 | 611 | 590 | 928 | 955 |
| EPS in Rs | 5.50 | 21.14 | 100.04 | 36.05 | 34.83 | 54.75 | 56.39 |
| Dividend Payout % | 727% | 142% | 90% | 89% | 92% | 99% |
Key Metrics
| TTM PE Ratio | PB Ratio | Dividend Yield | Sector PE | Sector PB | Sector Div Yld |
| 44.15 | 21.61 | 2.17% | 37.17 | 5.87 | 0.58% |
Peers & Comparison
| Stock | PE Ratio | PB Ratio | Dividend Yield |
| GlaxoSmithKline Pharmaceuticals Ltd | 45.46 | 21.61 | 2.17% |
| Sun Pharmaceutical Industries Ltd | 39.62 | 5.97 | 0.89% |
| Torrent Pharmaceuticals Ltd | 66.51 | 16.75 | 0.85% |
| Cipla Ltd | 23.35 | 3.93 | 1.05% |
Is Glaxosmi Pharma stock good to buy? (bull case & bear case)
Bull Case:
- This stock has a debt-to-equity ratio of around 0.02, showing very little debt.
- It has a Return on Capital Employed of around 57.7% meaning the company uses its capital efficiently to earn profits.
- It has a Return on Equity of around 56.5% indicating shareholders get good returns on their equity.
- This stock has an EPS of around ₹54.9 per share, showing that profit per share is healthy.
- It provides a dividend yield of around 2.15% offering some income to investors.
- This stock has a broad business mix including general medicines, vaccines and speciality treatments, which reduces risk from depending on a single product line.
Bear Case:
- This stock has a Price to Earnings ratio of around 44 to 45 times, meaning it is somewhat pricey given current earnings, and future growth is expected by the market.
- It provides a modest dividend yield of around 2.15% which may not be attractive for investors seeking high regular income.
- This stock’s growth depends on continuing performance and innovation, and if the company fails to deliver new products or execute well, it may affect returns.
Conclusion
It is a big medicine company in India. It makes regular medicines, vaccines, and special treatments for diseases like infections, HIV, cancer, and breathing problems. The company is strong and has little debt. It makes many different products, which makes it safer and more stable. Even though the stock price can be high and there are risks from competition and government rules, it is a good choice for steady long-term growth in healthcare.
